Navigation Links
Companion Diagnostics Market is Expected to Reach USD 5.6 Billion Globally in 2019: Transparency Market Research

ALBANY, New York, August 29, 2013 /PRNewswire/ --

According to a new market report published by Transparency Market Research ( "Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global companion diagnostics market was valued at USD 1.8 billion in 2012 and is expected to grow at a CAGR of 18.1% from 2013 to 2019, to reach an estimated value of USD 5.6 billion in 2019.

Browse the full report at

Companion diagnostics are the tests or assays which assist physicians in making efficient treatment decisions depending on the patient response to the ongoing treatment. These tests are developed either once the drug is commercialized or along with the drug in development. The diagnostic test acts as a companion to the drug under investigation and ensures the commercialization of a safer and efficient targeted therapeutic in a very cost effective manner. The most important factors favoring growth of the global companion diagnostics market include the increasing focus of pharmaceutical manufacturers on cost reduction in drug discovery and development, and the rising demand for targeted therapies. Also, continuous exploration of biomarkers and advances in diagnostic technologies will drive the growth and acceptance of companion diagnostics worldwide.

Factors such as lack of compact regulatory guidelines for the development and commercialization of companion diagnostics, high cost of procedures, lengthy developmental and approval phases, and lack of proper reach and availability (particularly in the low income countries) are expected to hamper the ready acceptance of companion diagnostics. Currently, many in vitro diagnostics companies are focusing on the development of accurate and reliable companion diagnostics for various biomarkers. Pharmaceutical companies are either focusing on in-house development of companion diagnostics or development in collaboration with diagnostics companies. This strategy focusing on the co-development of a drug and its companion diagnostic will prove to be advantageous over the conventional development process occurring in isolation.

The global companion diagnostics market can be categorized by tests for various indications and geography. Companion diagnostics market for breast cancer was the most prominent segment of the market in 2012 by revenue. Extensive research on breast cancer biomarkers and a paradigm shift towards personalized medicine will continue to propel the adoption of breast cancer companion diagnostics. However, another attractive segment of this market is that of lung cancer companion diagnostics, with the discovery of lung cancer specific biomarkers and an elaborate pipeline of related companion diagnostics for the same. It is estimated that the global market for lung cancer companion diagnostics will grow at a CAGR of over 20% from 2013 to 2019.

At a regional level, North America was the largest market in 2012 for companion diagnostics, followed by the European region. The favorable healthcare policies, large consumer base, high disposable incomes, increased awareness, presence of suitable infrastructure facilities and ready acceptance of novel approaches in medicine will propel rapid development of companion diagnostics in the North American market. The Asia-Pacific and RoW regions are expected to experience commendable growth by 2019 due to the huge untapped potential, rising disposable incomes and continuous improvements in healthcare infrastructure.

Related & Recently Published Reports by Transparency Market Research

In Vitro Diagnostics Market:

Pain Management Devices Market:

Microscopy Devices Market:

The companion diagnostics market is characterized by the presence of established diagnostics manufacturers as well as small players solely operating in this market. The major companies competing in this market are Roche Holdings AG, Qiagen N.V., Abbott Laboratories, Agilent Technologies, Inc., Genomic Health, Inc., GE Healthcare Ltd., Life Technologies Corporation, and Agendia N.V.

The global companion diagnostics market is segmented as follows:

Companion Diagnostics Market, by Indications

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Others (HIV, Thalassemia)

Companion Diagnostics Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Browse all Medical Devices Market Research Reports@

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

SOURCE Transparency Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
2. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
3. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
4. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
5. Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook
6. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
7. Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma
8. Medical Design Excellence Awards Selects Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart as Silver Winner
9. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization
10. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
11. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
Post Your Comments:
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
(Date:11/24/2015)... ... ... Whitehouse Laboratories is pleased to announce that it has completed construction on a ... basic USP 61, USP 62 and USP 51 testing specific to raw materials and ... testing performed by one supplier. Management has formally announced that the facility ...
(Date:11/23/2015)... , ... November 23, 2015 , ... ... for the development of its Nexera UC Unified Chromatography system. The award from ... technically significant new products of the year in the analytical and testing category. ...
(Date:11/23/2015)... , Nov. 23, 2015  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 2, 2015 at The New ... . Pat Mackin , President and Chief Executive ... Chief Executive Officer. --> A live webcast ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):